Cresilon has secured an Innovative Technology contract from Vizient for its hemostatic gel TRAUMAGEL following evaluation by hospital experts participating in the organization’s client-led councils. The Brooklyn-based biotechnology firm’s bleeding control product already holds U.S. Food and Drug Administration 510(k) clearance for temporary external use in controlling moderate to severe bleeding and is designed to deliver rapid hemorrhage control through a syringe-based hydrogel system.

The contract places TRAUMAGEL within Vizient’s purchasing ecosystem, which represents more than $156 billion in annual procurement activity across hospitals and health systems in the United States. While the designation does not mandate hospital adoption, it signals to procurement committees and clinical leaders that the technology has passed an innovation review conducted by hospital experts and may offer advantages compared with existing bleeding control options.

For medical device companies targeting hospital markets, this type of procurement recognition can be strategically important. Hospitals frequently rely on group purchasing organizations such as Vizient to streamline device evaluation and sourcing decisions, meaning technologies included in these networks gain greater visibility among hospital administrators, trauma surgeons, and emergency medicine teams.

Why Vizient’s procurement endorsement matters for medical device commercialization and hospital access

In the hospital device market, gaining clinical clearance is only one step toward widespread adoption. Procurement pathways often determine whether new technologies are evaluated by hospital committees in the first place. Group purchasing organizations act as intermediaries between manufacturers and healthcare systems, negotiating contracts and highlighting technologies that may deliver measurable improvements in patient care or operational efficiency.

Vizient is one of the largest such organizations in the United States, representing academic medical centers, community hospitals, pediatric hospitals, and integrated health systems. Through its Innovative Technology Program, the organization invites manufacturers to submit products for evaluation by clinical experts and procurement specialists. Products recommended by the councils are considered to have attributes that differentiate them from existing solutions.

Industry observers note that this recognition often serves as a signal to hospitals that a device has already undergone preliminary clinical and operational review. That endorsement can accelerate pilot deployments or trial usage within emergency departments, trauma units, and surgical environments. While hospitals still perform their own assessments, being listed under a recognized procurement contract removes a major administrative barrier to entry.

For Cresilon, the Vizient contract therefore represents more than symbolic validation. It provides structured access to one of the largest healthcare purchasing networks in the country, allowing hospital buyers to evaluate TRAUMAGEL through an established contracting framework.

How TRAUMAGEL’s hydrogel approach reflects broader innovation trends in hemorrhage control

The interest surrounding TRAUMAGEL reflects a broader shift in how trauma care teams approach bleeding control technologies. Hemorrhage remains one of the leading causes of preventable death in trauma cases, particularly in the early stages after injury. Emergency physicians and trauma surgeons therefore prioritize interventions that can rapidly stabilize bleeding before definitive surgical treatment.

Traditional bleeding control techniques often rely on pressure dressings, gauze-based hemostatic materials, surgical sutures, or electrocautery. While these approaches remain effective in many cases, clinicians have increasingly explored new technologies that reduce response time and simplify application during high-pressure trauma scenarios.

Flowable hemostatic gels represent one such emerging category. Unlike bandage-based materials that must be packed into wounds, flowable products can adapt to irregular wound shapes and reach deeper bleeding surfaces. This flexibility may improve performance in complex injuries where conventional materials are difficult to apply quickly.

TRAUMAGEL’s syringe-based design aims to address workflow limitations common in emergency medicine. The product is supplied in a prefilled sterile syringe and requires no mixing or preparation before use. This type of ready-to-use format can be valuable in trauma settings where clinicians must act quickly and often under challenging conditions.

Industry analysts tracking trauma device innovation note that technologies that simplify application and reduce preparation time tend to gain interest from emergency departments and trauma centers. However, real-world performance ultimately determines whether these technologies become standard tools in clinical practice.

What differentiates hydrogel-based bleeding control from conventional hemostatic agents

Cresilon’s technology relies on a proprietary hydrogel formulation designed to form a mechanical barrier at the bleeding site. Instead of primarily accelerating the body’s natural clotting process, the gel works by physically sealing the wound surface and helping stop blood flow quickly.

This mechanism distinguishes hydrogel-based hemostats from several traditional surgical bleeding control agents. Many existing products rely on materials such as collagen, oxidized cellulose, or thrombin to stimulate coagulation pathways. These agents encourage clot formation but may require more time to achieve full hemostasis in certain scenarios.

Hydrogel systems instead focus on immediate physical sealing. In theory, this approach can deliver faster bleeding control, particularly in traumatic injuries where rapid stabilization is critical.

However, clinicians evaluating the technology will likely consider several factors beyond initial bleeding control. One key question involves how the material behaves in high-pressure arterial bleeding environments. Another involves how easily the gel can be removed during surgical intervention after temporary stabilization.

Emergency physicians and trauma surgeons often emphasize that usability and reliability under real clinical conditions matter as much as laboratory performance metrics. Products that integrate smoothly into existing trauma workflows typically gain broader acceptance.

Why trauma device adoption depends on clinical evidence and workflow compatibility

Even when a new medical device demonstrates promising performance characteristics, widespread adoption within hospitals often requires a gradual process. Trauma departments typically evaluate new tools through controlled clinical use, allowing physicians and nurses to assess how well the product integrates into emergency response protocols.

Clinicians tend to prioritize technologies that reduce procedural complexity rather than introducing new operational burdens. Devices that require extensive preparation, specialized training, or additional steps may face resistance even if they offer theoretical benefits.

Cost considerations also play a role. Hospitals must balance innovation with financial constraints, particularly as healthcare systems face increasing pressure to control expenses. Procurement committees therefore examine whether new technologies provide measurable improvements in patient outcomes, workflow efficiency, or resource utilization.

In the case of hemostatic devices, adoption often depends on whether clinicians believe the technology improves response time during critical bleeding events. If emergency teams perceive a clear advantage in speed or ease of use, new products may gain traction quickly.

Conversely, if the performance difference appears marginal compared with existing materials, adoption may remain limited to niche use cases.

What Cresilon’s procurement milestone suggests about its broader commercialization strategy

Cresilon’s progress with TRAUMAGEL also reflects a broader commercialization strategy focused on hydrogel-based hemostatic technologies. The biotechnology firm has positioned its hydrogel platform as a foundation for multiple medical applications, including trauma care, biosurgery, and veterinary medicine.

For emerging medical device companies, scaling distribution and manufacturing after regulatory clearance is often one of the most challenging stages of commercialization. Partnerships with large purchasing networks can help overcome this hurdle by providing structured market access.

Industry watchers note that Cresilon’s ability to secure a Vizient Innovative Technology contract suggests the company is moving from early commercialization into a phase focused on institutional adoption. That shift typically involves expanding production capacity, strengthening hospital relationships, and generating real-world clinical data to support broader use.

The company’s future trajectory will likely depend on how well TRAUMAGEL performs in hospital trauma environments and whether clinicians advocate for its integration into standard bleeding control protocols.

Why the trauma hemostatic market is becoming increasingly competitive

Cresilon’s advancement occurs within a competitive medical device market that includes numerous established hemostatic technologies. Major surgical device manufacturers produce a range of bleeding control materials designed for operating rooms, trauma care, and battlefield medicine.

Many of these products have decades of clinical data and long-standing relationships with hospital systems. As a result, new entrants must demonstrate clear advantages to capture market share.

At the same time, advances in trauma medicine and military medical research have accelerated innovation in bleeding control technologies. Devices originally developed for battlefield injuries are increasingly being adapted for civilian trauma care, creating new opportunities for innovation.

This environment has encouraged manufacturers to explore technologies that emphasize rapid deployment, ease of use, and minimal preparation. Flowable hemostatic agents and hydrogel systems represent one example of this trend.

Whether such technologies become widely adopted will depend on clinical outcomes, physician experience, and cost considerations.

What clinicians and industry observers will watch as TRAUMAGEL expands hospital use

As TRAUMAGEL enters broader clinical evaluation across hospital systems, several factors will likely determine its long-term impact. Clinicians will closely monitor how quickly the product stops bleeding in real-world trauma scenarios and whether it performs consistently across different wound types.

Another area of interest will involve integration with existing trauma protocols. Emergency departments often operate under tightly defined procedures, meaning new technologies must fit seamlessly into established workflows.

Regulatory watchers may also examine post-market clinical data as hospitals gain experience with the product. Real-world evidence can play an important role in determining whether a technology evolves from an innovative option to a widely adopted standard of care.

Manufacturing scale and supply reliability will also be important if hospital demand increases. Medical device companies entering the trauma market must demonstrate the ability to deliver consistent product quality while meeting rising procurement volumes.

For Cresilon, the Vizient contract provides an important commercial foothold. However, the ultimate success of TRAUMAGEL will depend on clinical performance, physician acceptance, and the company’s ability to scale its hydrogel technology across multiple medical applications.

  Bleeding control technology, Cresilon, Emergency medicine technology, Hemorrhage control, Hemostatic gel, medical device innovation, Trauma care devices, TRAUMAGEL, Vizient